ENDRA Life Sciences prices $8M public offering of common stock and warrants

ENDRA Life Sciences Inc.

Gross proceeds ~$8M; offering closed June 5, 2024 with Craig-Hallum as placement agent.
61.5M units sold at $0.13 each (or pre-funded at $0.1299), each with Series A and B warrants.
Series A and B warrants exercisable at $0.22; Series B includes alternate cashless exercise at $0.001 for 3 shares.
Warrants require stockholder approval and charter amendment; lock-up of 90 days for company/insiders.
Net proceeds to be used for working capital and general corporate purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.